عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

First Red Sea Fashion Week Starts on Ummahat Islands

The event aims to establish Saudi fashion's presence in relevant international forums and position the Kingdom's fashion as a major contributor across various sectors of the fashion industry globally. SPA
The event aims to establish Saudi fashion's presence in relevant international forums and position the Kingdom's fashion as a major contributor across various sectors of the fashion industry globally. SPA
TT
TT

First Red Sea Fashion Week Starts on Ummahat Islands

The event aims to establish Saudi fashion's presence in relevant international forums and position the Kingdom's fashion as a major contributor across various sectors of the fashion industry globally. SPA
The event aims to establish Saudi fashion's presence in relevant international forums and position the Kingdom's fashion as a major contributor across various sectors of the fashion industry globally. SPA

The first Red Sea Fashion Week (RSFW) kicked Thursday from Ummahat Islands, promising three days of style and glamour at the St. Regis Red Sea Resort.
The RSFW, organized by the Saudi Fashion Commission, is a cultural and economic milestone for the fashion industry in the Kingdom, representing a prominent initiative that integrates Saudi fashion into the global market, SPA reported.
The event aims to establish Saudi fashion's presence in relevant international forums and position the Kingdom's fashion as a major contributor across various sectors of the fashion industry globally. It recognizes the significant impact of fashion as a contributor to national economies.
Fashion Commission chief executive Burak Cakmak expressed the goal of the RSFW to create a platform that fosters cultural exchange and celebrates creativity. He added that the cultural event highlights the commission's steadfast commitment to driving the fashion industry forward in the Kingdom.
He further emphasized the commission's dedication to creating an appealing environment where talented individuals, both male and female, from the nation can connect with experienced international figures and reputable entities in the industry.
With a meticulously planned schedule, the RSFW features an impressive lineup of Saudi and global brands that can adorn the nation’s platforms, showrooms, and forums at the local, regional and global levels, Cakmak said.
The Fashion Commission's strategies and plans revolve around nurturing local talents and integrating them into the global fashion scene, Cakmak said, aligning with the objectives of Saudi Vision 2030 to enrich the cultural fabric of the Kingdom.
Cakmak stressed the commission's eagerness to keep up with these objectives that also expand local economic horizons, with culture playing a vital role in the national product and contributing to the overall development of the country's economy.

Most Viewed

 
 
Varieties

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”